Sort
23,748 grants matching “melanoma”
Ultrasound imaging and local drug delivery in tumors
$707,248Katherine W Ferrara · University Of California At Davis · R01 · FY2011 · CA
Molecular Diagnostics And Support
$707,176Dave S B Hoon · Saint John'S Cancer Institute · P01 · FY2013 · CA
A Genetic Linkage Study of Testicular Cancer
$707,172Victoria K Cortessis · University Of Southern California · R01 · FY2007 · CA
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
$707,046David L Wiest · Research Inst Of Fox Chase Can Ctr · R01 · FY2023 · CA
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
$707,044David L Wiest · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA
A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers
$706,771Peter A Kanetsky · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Molecular Analysis of Melanoma Metastasis and Blood in Patients Undergoing Sentin
$706,707Dave S B Hoon · Saint John'S Cancer Institute · P01 · FY2012 · CA
The MB-CCOP at Boston Medical Center
$706,684Lisa A. Kachnic · Boston Medical Center · U10 · FY2010 · CA
Immunotherapy to deplete key Treg subsets in solid tumors
$706,495Peter David Suzdak · Sonoval Llc · R44 · FY2025 · CA
Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy
$706,425Sonia Sharma · La Jolla Institute For Immunology · R01 · FY2022 · CA
Interrogating unique DC adaptations to tissue to promote barrier immunity and tolerance
$706,103Niroshana Anandasabapathy · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · AR
Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy
$706,097Sonia Sharma · La Jolla Institute For Immunology · R01 · FY2023 · CA
Nitro-Fatty Acids and Cardiovascular Disease
$706,029Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2024 · HL
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors
$705,888Craig M. Brackett · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
$705,863Michael John Becich · University Of Pittsburgh At Pittsburgh · U24 · FY2017 · CA
The Genetics of Susceptibility to Mouse Plasma Cell Tumors
$705,449Beverly Mock · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Nuclear receptors: action, functions, and roles in disease
$704,937Anton M Jetten · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$704,431Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade
$704,403Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2020 · CA
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1
$703,389Jane Amanda Skok · New York University School Of Medicine · R01 · FY2025 · CA
Retinoic Acid Induced Lymphangiogenesis for Post-surgical Lymphedema
$703,342Alex K. Wong · Beckman Research Institute/City Of Hope · R01 · FY2023 · HL
Role of GPNMB in cardiac remodeling
$702,950Arjun Deb · University Of California Los Angeles · R01 · FY2021 · HL
Tumor-derived extracellular vesicles in the pre-metastatic niche.
$702,906Yves A Declerck · Children'S Hospital Of Los Angeles · R01 · FY2024 · CA
Plasma-based therapies for bone infection: A tripartite USA/Northern Ireland/Republic of Ireland consortium
$702,816Theresa A Freeman · Thomas Jefferson University · R01 · FY2020 · AR
Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies
$702,748Taha Merghoub · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA